Cardiovascular Complications in Respiratory Viral Infections with a Focus on COVID-19

  • Elahe Aleebrahim-Dehkordi Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Shahrekord, Iran
  • Mehdi Mohebalizadeh School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
  • Zahra Ganjirad Hamedan University of medical sciences, Hamedan, Iran
  • Sara Torabi School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Dariush Hooshyar School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  • Amene Saghazadeh Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
Keywords: Cardiovascular; COVID-19; Influenza; MERS; Respiratory Viral Infections; SARS

Abstract

Patients with respiratory viral infections have altered immune responses, which may predispose them to cardiovascular complications. In the face of the pandemic of a new kind of severe acute respiratory syndrome (SARS), coronavirus disease 2019 (COVID-19), there is a resurgence of interest in the early diagnosis, prevention, and treatment of patients who are at risk. COVID-19 often manifests as viral pneumonia, although extrapulmonary manifestations are also common. Acute cardiac damage associated with elevated highsensitivity troponin levels crucially contributes to mortality in severe COVID-19. The present review clinically compares cardiovascular complications between COVID-19 and other respiratory infections caused by singlestranded RNA viruses, namely influenza, SARS, and Middle East respiratory syndrome (MERS). Estimating the death rate from RVIs has been a subject of intense research, but the mortality from cardiovascular complications in these infections is less understood and calls for further research.

Published
2024-09-01
Section
Articles